TCGA-D8-A1JJ-01A-31R-A14M-07
— · C
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- C
- subtype
- C
- overall_survival_months
- 20
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MTORC1_SIGNALING+0.470
- ANDROGEN_RESPONSE+0.460
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.430
- G2M_CHECKPOINT+0.380
- MITOTIC_SPINDLE+0.380
- PROTEIN_SECRETION+0.370
- E2F_TARGETS+0.360
- MYC_TARGETS_V1+0.350
- PI3K_AKT_MTOR_SIGNALING+0.310
- UNFOLDED_PROTEIN_RESPONSE+0.300
Top 10 suppressed
- WNT_BETA_CATENIN_SIGNALING-0.310
- KRAS_SIGNALING_DN-0.220
- ESTROGEN_RESPONSE_EARLY-0.200
- ESTROGEN_RESPONSE_LATE-0.180
- TNFA_SIGNALING_VIA_NFKB-0.170
- ADIPOGENESIS-0.140
- XENOBIOTIC_METABOLISM-0.120
- APICAL_SURFACE-0.110
- OXIDATIVE_PHOSPHORYLATION-0.090
- ALLOGRAFT_REJECTION-0.080
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MNG56 | — | — | 0.809 |
| 2 | 131540 | EPN | EPN Tumor | 0.794 |
| 3 | SRR4195688 | — | — | 0.769 |
| 4 | SRR934935 | — | — | 0.762 |
| 5 | TCGA-DK-A1A5-01A-11R-A13Y-07 | — | — | 0.757 |
| 6 | TCGA-AN-A0G0-01A-11R-A034-07 | — | E | 0.749 |
| 7 | TCGA-E9-A1RH-01A-21R-A169-07 | — | C | 0.748 |
| 8 | MDT-AP-3249 | Med | Medulloblastoma | 0.748 |
| 9 | HLF_LIVER | HCC | — | 0.748 |
| 10 | 47c0b7df-a564-4e71-8d90-ba07bac40f59 | — | — | 0.747 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 32 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MTORC1_SIGNALING | 0.470 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.460 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.430 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.380 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.380 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.370 | Remibrutinib | — uncovered |
| E2F_TARGETS | 0.360 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.350 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.310 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.300 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.270 | Inavolisib | — uncovered |
| HYPOXIA | 0.270 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.230 | Remibrutinib | — uncovered |
| ANGIOGENESIS | 0.220 | Remibrutinib | — uncovered |
| NOTCH_SIGNALING | 0.190 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.150 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.140 | Inavolisib | — uncovered |
| COMPLEMENT | 0.110 | Inavolisib | — uncovered |
| COAGULATION | 0.100 | Binimetinib | — uncovered |
| TGF_BETA_SIGNALING | 0.100 | Inavolisib | — uncovered |